MedPath

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation

Phase 2
Conditions
Lung Adenocarcinoma
EGFR Mutation
Interventions
Drug: gefitinib
Drug: Berberine
First Posted Date
2018-04-03
Last Posted Date
2018-04-03
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
50
Registration Number
NCT03486496
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

Phase 2
Conditions
Squamous Cell Carcinoma
Interventions
Drug: Afatinib
First Posted Date
2018-04-03
Last Posted Date
2018-04-03
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
2
Registration Number
NCT03486509

Next-generation Sequencing in Gastrointestinal Cancer

Conditions
Gastrointestinal Cancer
Interventions
Diagnostic Test: Device： NGS sequencing cfDNA
First Posted Date
2018-03-23
Last Posted Date
2018-07-02
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
200
Registration Number
NCT03476057
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

Phase 1
Withdrawn
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: S-1
Drug: Irinotecan
Drug: Bevacizumab
First Posted Date
2017-12-21
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03380689
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Phase 3
Completed
Conditions
Cancer Pain
Interventions
Drug: Hydromorphone
Device: PCA pump
First Posted Date
2017-12-18
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
214
Registration Number
NCT03375515
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

Phase 2
Conditions
NSCLC Stage IV
Chemotherapy Effect
Interventions
Drug: Thalidomide
First Posted Date
2017-11-14
Last Posted Date
2017-11-14
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
128
Registration Number
NCT03341494
Locations
🇨🇳

Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China

🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Phase I Study of the Combination of Apatinib and POF

Phase 1
Conditions
Gastric Adenocarcinoma
Interventions
Drug: Apatinib
Drug: POF
First Posted Date
2017-08-10
Last Posted Date
2018-01-26
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
18
Registration Number
NCT03244774
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

Conditions
SCLC
First Posted Date
2017-08-10
Last Posted Date
2017-08-10
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
80
Registration Number
NCT03244904

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

Phase 2
Withdrawn
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Levoleucovorin
Drug: 5-FU
Drug: GM-CSF
Drug: IL-2
First Posted Date
2017-07-19
Last Posted Date
2018-03-27
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03222089
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

Phase 2
Conditions
Advanced Gastric Cancer
Interventions
Drug: Docetaxel
Drug: S-1
First Posted Date
2017-05-02
Last Posted Date
2017-05-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
47
Registration Number
NCT03137004
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy